The PROPEL® advantage

PROPEL Steroid-Releasing Implant

Opens. Delivers. Maintains.

Intersect ENT has developed the PROPEL dissolvable implant for chronic sinusitis patients undergoing sinus surgery; the first and only sinus surgery product backed by Level 1-A evidence. PROPEL is the first of a new category of products offering localized, controlled drug delivery directly to the sinus tissue. Inserted by a physician to maintain the surgical opening, the spring-like implant expands to prop open the ethmoid sinus and gradually delivers an advanced corticosteroid (mometasone furoate) with anti-inflammatory properties directly to the sinus lining as the implant dissolves.

The PROPEL system has been clinically proven to prevent obstruction of the ethmoid sinus following surgery. The result is improved post-operative outcomes, reducing the need for additional surgical procedures such as adhesion lysis and systemic steroids.

ENT Surgeons can learn more about the PROPEL mometasone furoate implant by contacting Intersect ENT.

Click here for Instructions for Use.

Caution: Federal law (USA) restricts this product to sale by or on the order of a physician.

patient story

A chronic sinusitis patient recently featured on NBC news.

Patient Video

Introducing

Publications

Kennedy DW.
The PROPEL steroid releasing bioabsorbable implant to improve outcomes of sinus surgery.
Expert Review of Respiratory Medicine. 2012; 6(5):493-498.

Han JK, Marple BF, Smith TL et al.
Effect of steroid-releasing sinus implants on post-operative medical and surgical interventions.
Int Forum Allergy Rhinol. 2012; 2:271-279.

View all publications

FIND A PROPEL PHYSICIAN NEAR YOU!

Please fill in your contact information below and an Intersect ENT representative will respond within 2-3 business days. Thanks for your interest.

* Required fields

YOUR REQUEST HAS BEEN SUBMITTED.

An Intersect ENT representative will respond within 2-3 business days.

CLOSE THIS WINDOW

Courtesy of NBC Bay Area